MASTL promotes cell contractility and motility through kinase-independent signaling.


Journal

The Journal of cell biology
ISSN: 1540-8140
Titre abrégé: J Cell Biol
Pays: United States
ID NLM: 0375356

Informations de publication

Date de publication:
01 06 2020
Historique:
received: 28 06 2019
revised: 03 02 2020
accepted: 11 03 2020
entrez: 21 4 2020
pubmed: 21 4 2020
medline: 20 3 2021
Statut: ppublish

Résumé

Microtubule-associated serine/threonine-protein kinase-like (MASTL) is a mitosis-accelerating kinase with emerging roles in cancer progression. However, possible cell cycle-independent mechanisms behind its oncogenicity remain ambiguous. Here, we identify MASTL as an activator of cell contractility and MRTF-A/SRF (myocardin-related transcription factor A/serum response factor) signaling. Depletion of MASTL increased cell spreading while reducing contractile actin stress fibers in normal and breast cancer cells and strongly impairing breast cancer cell motility and invasion. Transcriptome and proteome profiling revealed MASTL-regulated genes implicated in cell movement and actomyosin contraction, including Rho guanine nucleotide exchange factor 2 (GEF-H1, ARHGEF2) and MRTF-A target genes tropomyosin 4.2 (TPM4), vinculin (VCL), and nonmuscle myosin IIB (NM-2B, MYH10). Mechanistically, MASTL associated with MRTF-A and increased its nuclear retention and transcriptional activity. Importantly, MASTL kinase activity was not required for regulation of cell spreading or MRTF-A/SRF transcriptional activity. Taken together, we present a previously unknown kinase-independent role for MASTL as a regulator of cell adhesion, contractility, and MRTF-A/SRF activity.

Identifiants

pubmed: 32311005
pii: 151688
doi: 10.1083/jcb.201906204
pmc: PMC7265322
pii:
doi:

Substances chimiques

ARHGEF2 protein, human 0
Integrins 0
MRTFA protein, human 0
Microtubule-Associated Proteins 0
Proteome 0
RNA, Small Interfering 0
Rho Guanine Nucleotide Exchange Factors 0
TPM4 protein, human 0
Trans-Activators 0
Tropomyosin 0
VCL protein, human 0
Vinculin 125361-02-6
MASTL protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Nonmuscle Myosin Type IIB EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Cancer Research UK
ID : A17196
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A12935
Pays : United Kingdom
Organisme : European Research Council
ID : 615258
Pays : International
Organisme : Cancer Research UK
ID : A12935
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P01058X/1
Pays : United Kingdom

Informations de copyright

© 2020 Taskinen et al.

Références

Trends Cell Biol. 2008 May;18(5):210-9
pubmed: 18394899
Nat Commun. 2016 Dec 02;7:13297
pubmed: 27910855
EMBO J. 2003 Jun 16;22(12):3050-61
pubmed: 12805219
J Clin Invest. 2018 Dec 3;128(12):5351-5367
pubmed: 30252678
Dev Cell. 2012 Mar 13;22(3):573-84
pubmed: 22387001
J Cell Biol. 2006 May 8;173(3):383-94
pubmed: 16651381
Science. 2013 May 17;340(6134):864-7
pubmed: 23558171
Lab Chip. 2009 Jun 7;9(11):1640-2
pubmed: 19458875
Nat Cell Biol. 2005 Oct;7(10):947-53
pubmed: 16179950
Cancer Lett. 2019 Feb 1;442:362-372
pubmed: 30445205
J Cell Sci. 2015 Jun 15;128(12):2209-17
pubmed: 26021351
Cell Cycle. 2010 Sep 1;9(17):3591-601
pubmed: 20818157
Bioarchitecture. 2011 Jul;1(4):135-164
pubmed: 22069507
Nat Commun. 2018 Apr 20;9(1):1581
pubmed: 29679077
PLoS Comput Biol. 2017 May 25;13(5):e1005562
pubmed: 28542205
Mol Cancer Ther. 2015 Jun;14(6):1434-44
pubmed: 25808837
Dev Cell. 2012 Aug 14;23(2):397-411
pubmed: 22898781
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
Sci Rep. 2018 Mar 20;8(1):4894
pubmed: 29559668
PLoS One. 2013 Aug 02;8(8):e69947
pubmed: 23936361
Nat Cell Biol. 2013 Aug;15(8):958-66
pubmed: 23851486
Cell Cycle. 2016;15(4):528-39
pubmed: 26761639
Nat Rev Mol Cell Biol. 2015 Aug;16(8):486-98
pubmed: 26130009
Nat Cell Biol. 2011 Jun;13(6):722-7
pubmed: 21572419
Nat Commun. 2017 Aug 8;8(1):206
pubmed: 28785014
Nat Cell Biol. 2009 Mar;11(3):257-68
pubmed: 19198601
Curr Opin Cell Biol. 2010 Feb;22(1):50-6
pubmed: 20031383
Cell Cycle. 2017 Sep 17;16(18):1695-1704
pubmed: 28783414
Curr Biol. 2011 Apr 12;21(7):539-50
pubmed: 21458264
Front Cell Dev Biol. 2018 Nov 23;6:162
pubmed: 30555827
F1000Res. 2013 Mar 04;2:68
pubmed: 24358855
J Cell Sci. 2017 Oct 15;130(20):3427-3435
pubmed: 29032357
J Cell Sci. 2007 Jan 1;120(Pt 1):137-48
pubmed: 17164291
Curr Biol. 2008 Jan 22;18(2):91-101
pubmed: 18207738
J Cell Sci. 2008 Sep 1;121(Pt 17):2795-804
pubmed: 18682496
Genes Dev. 2014 May 1;28(9):943-58
pubmed: 24732378
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
J Cell Biol. 2017 Oct 2;216(10):3087-3095
pubmed: 28774893
Cell. 2003 May 2;113(3):329-42
pubmed: 12732141
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Int J Dev Biol. 2016;60(7-8-9):245-254
pubmed: 27759153
Elife. 2015 Nov 27;4:
pubmed: 26613407
Mol Cell Biol. 2008 Jan;28(2):732-42
pubmed: 18025109
Sci Rep. 2016 Feb 29;6:22230
pubmed: 26923777
Nat Methods. 2012 Jul 01;9(8):825-7
pubmed: 22751201
Cell Death Differ. 2018 May;25(5):828-840
pubmed: 29229993
Nucleic Acids Res. 2010 Jan;38(Database issue):D142-8
pubmed: 19843607
BMC Cancer. 2018 Jul 5;18(1):716
pubmed: 29976159
Nature. 2010 May 20;465(7296):373-7
pubmed: 20485438
Mol Biol Cell. 2002 Dec;13(12):4167-78
pubmed: 12475943
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Science. 2009 Nov 27;326(5957):1208-12
pubmed: 19965462
Nat Rev Mol Cell Biol. 2010 May;11(5):353-65
pubmed: 20414257
J Cell Sci. 2014 Jun 1;127(Pt 11):2542-53
pubmed: 24681784
Curr Biol. 2017 Mar 6;27(5):705-713
pubmed: 28216317
J Cell Biol. 2008 Feb 25;180(4):739-46
pubmed: 18283112
Am J Physiol Cell Physiol. 2013 Jan 15;304(2):C115-27
pubmed: 23054059
Oncogene. 2018 Aug;37(33):4518-4533
pubmed: 29743597
Nat Immunol. 2014 Jan;15(1):63-71
pubmed: 24270516
Dev Cell. 2005 May;8(5):777-86
pubmed: 15866167
Bioinformatics. 2008 Jul 1;24(13):1547-8
pubmed: 18467348
Cancer Cell. 2014 Feb 10;25(2):181-95
pubmed: 24525234
Nat Cell Biol. 2006 Mar;8(3):215-26
pubmed: 16501565
J Muscle Res Cell Motil. 2015 Apr;36(2):147-53
pubmed: 25369766
J Cell Sci. 2018 Oct 11;131(19):
pubmed: 30309957
Science. 2007 Jun 22;316(5832):1749-52
pubmed: 17588931
Biophys J. 2013 Aug 6;105(3):547-54
pubmed: 23931302
Nucleic Acids Res. 2008 Feb;36(2):e11
pubmed: 18178591

Auteurs

Maria Emilia Taskinen (ME)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Elisa Närvä (E)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

James R W Conway (JRW)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Laura Soto Hinojosa (LS)

Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, and Center for Integrative Biological Signalling Studies, Freiburg, Germany.

Sergio Lilla (S)

Cancer Research UK Beatson Institute, Glasgow, UK.

Anja Mai (A)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Nicola De Franceschi (N)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Laura L Elo (LL)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Robert Grosse (R)

Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, and Center for Integrative Biological Signalling Studies, Freiburg, Germany.

Sara Zanivan (S)

Cancer Research UK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Jim C Norman (JC)

Cancer Research UK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Johanna Ivaska (J)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Department of Biochemistry, University of Turku, Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH